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Background: Evaluating the cost-effectiveness of breast cancer screening requires estimates of the absolute risk of
breast cancer, which is modified by various risk factors. Breast cancer incidence, and thus mortality, is altered by the
occurrence of competing events. More accurate estimates of competing risks should improve the estimation of
absolute risk of breast cancer and benefit from breast cancer screening, leading to more effective preventive,
diagnostic, and treatment policies. We have previously described the effect of breast cancer risk factors on breast
cancer incidence in the presence of competing risks. In this study, we investigate the association of the same risk
factors with mortality as a competing event with breast cancer incidence.
Methods: We use data from the Canadian National Breast Screening Study, consisting of two randomized
controlled trials, which included data on 39 risk factors for breast cancer. The participants were followed up for the
incidence of breast cancer and mortality due to breast cancer and other causes. We stratified all-cause mortality
into death from other types of cancer and death from non-cancer causes. We conducted separate analyses for
cause-specific mortalities.
Results: We found that “age at entry” is a significant factor for all-cause mortality, and cancer-specific and non-
cancer mortality. “Menstruation length” and “number of live births” are significant factors for all-cause mortality, and
cancer-specific mortality. “Ever noted lumps in right/left breasts” is a factor associated with all-cause mortality, and
non-cancer mortality.
Conclusions: For proper estimation of absolute risk of the main event of interest common risk factors associated
with competing events should be identified and considered.
Keywords: Invasive breast cancer, Competing mortality, Cancer-specific mortality, Non-cancer mortality, Risk factorsBackground
Women in a clinical trial with breast cancer incidence as
the endpoint may die due to causes other than breast
cancer before the occurrence of the cancer. Competing
events should be taken into account in evaluating the ef-
ficacy and cost-effectiveness of screening interventions
both at the population level and for a given individual
(personalized screening regimes). A specific screening
intervention may be recommended for a woman based* Correspondence: sharareh@ryerson.ca
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distribution, and reproduction in any mediumon her age and other characteristics, such as having a
family history of breast cancer. However, these charac-
teristics can also affect the occurrence of competing
events; so, it is essential to study the effect of risk factors
on both breast cancer incidence and its competing
events such as mortality due to other causes.
Some studies have focused on the main event of inter-
est and considered competing risks. Fang et al. [1] exam-
ined the potential role of nonsteroidal anti-inflammatory
drugs on prostate cancer specific mortality while con-
trolling for other competing causes of death. Yi et al. [2]
determined the factors associated with a contralateral
prophylactic mastectomy while taking into account thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cancer. Mell et al. [3] identified predictors of non-cancer
causes of death in head and neck cancer and developed
a risk stratification model for these competing events.
Mell et al. [4] used competing risk modeling to identify
predictors of non-cancer mortality in women with early
breast cancer, while considering disease recurrences as
competing risks.
Other studies focused on all competing events and
investigated the effect of some risk factors on the main
event of interest and its competing risks. Several studies
used cohort life tables to derive probability estimates for
death due to breast cancer as well as mortality due to
other causes. Hence, they were able to estimate reduc-
tions in breast cancer mortality [5,6]. Lambert et al. [7]
estimated and partitioned the crude probability of all-
cause mortality to the probabilities due to cancer and
other causes. Crude probabilities can be used to under-
stand the impact of disease on individual patients and
help assess different treatment options. Daskivich et al.
[8] assessed the competing risks of mortality from non-
prostate cancer on patients with prostate cancer. Barnes
et al. [9] emphasized that some risk factors associated
with breast cancer have been shown to affect the risk of
other health outcomes, so competing risks and benefits
may influence public health policy decisions. Vilaprinyo
et al. [6] estimated the risk of death from causes other
than breast cancer; used for assessing the effect of mam-
mography screening on breast cancer mortality.
In another study [10], we have investigated the associ-
ation of 39 risk factors with breast cancer incidence in
the presence of competing risk. We used data from the
Canadian National Breast Screening Study (CNBSS) in
which the information on risk factors were collected at
enrolment or recorded by a nurse or physician at the ini-
tial physical examination of the breasts. In the CNBSS,
women were enrolled alive and had to be cancer-free.
They were randomly assigned to study and control
groups and were followed up for breast cancer incidence
and mortality. By the end of the study period, a woman
might have been diagnosed with breast cancer, died from
any causes including breast cancer, or remained alive
and cancer-free. A schematic illustration of the three
possible terminating points is shown in Figure 1.(0) Alive and cancer-free
(1) Invasive breast cancer
(2) All-cause mortality  
except breast cancer 
Figure 1 Schematic illustration of the three terminating points
in the study.The main focus of the current study and of [10] is on
breast cancer incidence and its risk prediction model.
Therefore, in these two studies, we terminate the follow-
up of a woman as soon as she is diagnosed with breast
cancer. Thus, we do not study the progression of a
tumor from diagnosis to death.
Breast cancer incidence and mortality due to non-
breast cancer causes are competing risks and both
should be analyzed. The necessity of studying both
events is given in detail in Discussion section of the
paper. In this paper, we investigate the effect of 39 risk
factors on mortality due to causes other than breast can-
cer. So, the current paper and [10] are complimentary.
We identify the factors common to both breast cancer
incidence and competing mortality. In addition, we strat-
ify all-cause mortality (excluding breast cancer), compar-
ing it to death caused by other types of cancer and death
from non-cancer causes. We conduct separate analyses
for all-cause mortality and the two cause-specific mor-
talities. The reason for stratification is to examine
whether any of the risk factors are particularly associated
with both breast cancer incidence and cancer mortality.
The findings in this case are more informative and help
us understand better the biological mechanism through
which a risk factor influences cancer and non-cancer
mortality.
Methods
Study Population and Period
The Canadian National Breast Screening Study (CNBSS)
has been described previously [10-12]. Its main objective
is to assess the effect of mammography in reducing
breast cancer mortality. The study consists of two ran-
domized controlled trials of 89,835 women; 50,430 aged
40–49 and 39,405 aged 50–59. The women were
recruited at 15 Canadian centres between 1980 and
1985. All participants signed an informed consent form
developed with approval from the University of Toronto
Human Experimentation Committee when they enrolled
in the CNBSS which included explicit agreement for
linkage to vital statistics records and analysis of the data
in the future. Women in the age group 40–49 were ran-
domly selected to receive either an annual mammogram
and physical examination (intervention group) or only
an initial physical examination with no mammography
(control group). Women aged 50–59 were randomly
selected to receive either an annual mammogram and
physical examination (intervention group) or an annual
physical examination only (control group). A flow dia-
gram of the CNBSS is presented in Figure 2.
Woman in the CNBSS were not pregnant at the time
of enrolment, had no history of breast cancer and no
mammogram in the past 12 months. At enrolment, they
completed enrolment and epidemiology questionnaires
Analytical cohort of
89,835women aged 40-59
19,711 women aged 50-59 received 
annual mammography and physical 
examination
19,694 women aged 50-59 received 
annual physical examination
25,214 women aged 40-49 received 
annual mammogram and physical 
examination
25,216 women aged 40-49 received a 
single physical examination with no 
mammography
44,925 women in 
the intervention group
44,910 women in 
the control group
Figure 2 A flow diagram of the CNBSS.
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family history of breast cancer, and personal history of
breast disease. Moreover, at enrolment a nurse or phys-
ician performed a physical examination of the breasts
and recorded information on several risk factors.
The CNBSS contains information on breast cancer
diagnoses reported for women in the intervention group;
these women received up to five mammograms. In
addition, breast cancer diagnoses were identified by rec-
ord linkage with the National Cancer Registry and
deaths through linkage with the Canadian Mortality
Database at Statistics Canada for both the control and
the intervention groups after the annual screenings had
ended.
For this analysis we consider 1980–1989 as the study
period and exclude breast cancers which were diagnosed
less than six months after enrolment to eliminate long-
term prevalent breast cancers.
A total of 89,434 women were considered in our study:
of these, 944 were diagnosed with invasive breast cancer,
922 died from causes other than breast cancer (Table 1
describes the causes of death for these 922 women), and
87,568 were neither diagnosed with breast cancer nor
had died from other causes by the end of 1989. Of the
922 who died from causes other than breast cancer, 536
died from cancers other than breast cancer, and 386
deaths were due to non-cancer causes.Risk Factors and Data Preparation
This study considers 39 risk factors (see Tables 2, 3 4, 5)
collected at enrolment or recorded by a nurse or phys-
ician at the initial physical examination of the breasts.
We classify these factors into four groups: socio-
demographic factors, reproductive factors, lifestyle and
health behaviours, and history of breast disease. For a
premenopausal woman, “menstruation length” is the dif-
ference between her “age at entry” and “age atmenarche”, and for a postmenopausal woman, it is the
difference between her “age at the last menstrual period”
and “age at menarche”. Less than 5 % of the values of all
data were missing and have been imputed. A normal lin-
ear regression model is used to impute missing values in
the continuous variables. Missing values in the categor-
ical variables are imputed using a logistic or generalized
logistic model. Each woman is given a score for families/
relatives with breast cancer. Each relative, depending on
her degree (first, second, third, fourth, fifth degree and
above) makes a contribution of 2 6degree numberð Þ to the
score value. For example, a woman with one first degree
and one second degree relative with breast cancer is
given a score of 2 61ð Þ þ 2 62ð Þ ¼ 48. A woman with no
relatives with breast cancer receives a score of 1 [10].
The calculation method for score value is adapted from
the U.S. Preventive Services Task Force recommenda-
tions on genetic risk assessment and BRCA mutation
testing for breast and ovarian cancer susceptibility [13].
Statistical Method
In this study, we use multivariate cause-specific Cox re-
gression analysis to investigate the associations of the 39
risk factors with all-cause mortality, cancer-specific mor-
tality, and non-cancer mortality. Incidence of breast can-
cer is considered a competing event in the analysis of
all-cause mortality. In our analysis of the cause-specific
mortality from cancer and non-cancer causes, mutually
exclusive events are the competing events. For example,
breast cancer incidence and non-cancer mortality are
considered events competing with cancer-specific
mortality.
It should be noted that hazard of subdistribution pro-
posed by Fine and Gray [14] is another method for re-
gression modeling of an event in the presence of
competing risks. The hazard of subdistribution can be
used for directly modeling the effect of covariates on the
Table 1 Causes of deaths
Death Cause # Of Cases (n = 922)
Other cancers (excluding breast) (n = 536)
- Lung cancer 126
- Colon cancer 64
- Ovarian cancer 59
- Pancreatic cancer 48
- Other sites 239
Non cancer deaths (n = 386)
- Infections and Parasitic Diseases 5
- Endocrine, nutritional and metabolic diseases and immunity disorders 18
- Diseases of blood and blood forming organs 1
- Diseases of nervous system and sense organs 17
- Diseases of the circulatory system 183
- Diseases of the respiratory system 18
- Diseases of the digestive system 27
- Diseases of the genitourinary system 3
- Diseases of the musculoskeletal system and connective tissue 3
- Congenital anomalies 3
- Symptoms, signs and ill-defined conditions 7
- Injury and poisoning 25
- Factors influencing health status 1 (allergy)
- External causes 74
- Unknown 1
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cause-specific model must be used when the goal is to
investigate the biological effect of risk factors on the
event of interest [15]. We also fitted the Fine-Gray
model to our data and obtained very similar results to
those obtained from the cause-specific hazard model.
Results from the hazard of subdistribution model are
not shown in this paper due to space limitations. We
use the procedure PHREG in SAS v. 9.3 (SAS Institute,
Cary, NC) to build regression models. To construct the
models we first conduct univariate analysis of each indi-
vidual variable, we then combine the significant factors
in a multivariate model to adjust the risk for all signifi-
cant factors. Moreover, we perform a backward model
selection to recheck the final model. We considered a
variable (risk factor) statistically significant if its prob-
ability (P) value was less than 0.05.
We checked the interaction of the variables with each
other and with time to event (time of death or censoring
time) to find those variables with a time-varying effect
on the risk of mortality. No interaction terms were
found to be statistically significant.
In Figure 3, we used a non-parametric method formu-
lated by Kalbfleisch and Prentice [16] to estimate cause-specific hazard and obtained a discrete estimate of the
cumulative incidence function (cumulative risk). For this




From 89,434 participants in the study, 1.06% (N= 944)
were diagnosed with invasive breast cancer, 1.03%
(N= 922) died from causes other than breast cancer, and
97.9 % (N= 87,568) were alive and not diagnosed with
breast cancer by the end of 1989. 58.1% (N= 536) of the
deaths were due to other types of cancer, and 41.9%
(N= 386) due to causes other than cancer. The mean
times from enrolment to cancer diagnosis and to death
are 3.52 (SD 2.0) and 4.26 (SD 2.17) years respectively.
The median from enrolment to cancer diagnosis and to
death are respectively 3.18 and 4.23 years.
The mean and median follow-up time of women in
the censored group (alive and cancer-free by the end of
the study) are 6.72 (SD 1.32) and 6.39 years, respectively.
Figure 3.A shows the observed ten-year cumulative risk
of invasive breast cancer and all-cause mortality (exclud-
ing breast cancer death) stratified by two age-groups
Table 2 Characteristics of the study cohort: Socio-demographic factors
Variable n= 89434(%)




















Ever Married 84046 (93.98)
Never Married 5388 (6.02)
Occupations
Homemakers 31186 (34.86)
Clerical Occupations 18922 (21.16)
Social sciences, religion, teaching, artistic, literary and related 9808 (10.97)
Medicine and health 8405 (9.40)
Administrative and Managerial 6026 (6.74)
Sales Occupations 4836 (5.41)
Service Occupations-food and personal service 3460 (3.87)
Processing, machining, fabricating, and construction occupations 1187 (1.33)
Natural sciences, engineering and math 684 (0.76)
Transport, material handling, equipment operating 622 (0.70)
Farming, forestry and fishing 567 (0.63)
Others 3731 (4.17)
Allocation group
No mammography 44744 (50.03)
Mammography 44690 (49.97)
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always higher than the risk of all-cause mortality for
younger women (40–49) within the follow-up period.
However, for older women (50–59), although breast can-
cer incidence is lower than the risk of death in about the
first six years of follow-up; the curves for breast cancerincidence and all-cause mortality cross at this point and
the probability of death is higher than breast cancer inci-
dence subsequently.
Figure 3.B shows the ten-year cumulative risk of
breast cancer incidence, cancer-specific mortality,
and non-cancer mortality stratified by the two age-














Menstruation length (years) (meanSD) 32.10(5.85)




























Age at first child birth
N/A 13173 (14.73)
14-19 8345 (9.33)
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mortality curves in both age groups, we see that the
women in our study always have a higher probability
of breast cancer incidence than cancer-specific and
non-cancer mortality. Moreover, although for women
aged 40–49 the risk of death from cancer and non-
cancer causes is similar in the first two and half
years of follow-up, death from cancer is more likely
to occur than death from non-cancer causes after-
wards. For women in the age-group 50–59, death
from cancer is more likely to occur than non-cancer
mortality in the entire follow-up period. The prob-
ability estimates and their standard errors for breast
cancer incidence, cancer mortality, and non-cancer
mortality at eight years after follow-up are 0.013
(0.00047), 0.007 (0.00037), and 0.006 (0.00033) re-
spectively, for the overall population.
Predictors of All-cause Mortality
Table 6 presents the factors found to be statistically
significant for all-cause mortality. The reference
levels of the categorical variables are also shown in
the table. As an example, “1-2 children” is the refer-
ence level for “number of live births”. For continu-
ous variables, such as age or menstruation length,
the hazard ratio is the change in the hazard for a
one-unit increase in the value of the variable, hold-
ing all other variables constant. The results show
that older women have higher risk of all-cause mor-
tality (HR 1.12, 95% CI 1.10-1.13). For example,
compared to a 40-year old woman with the same
characteristics, a woman aged 50 at enrolment is al-
most three times (1:11810  3:00) more likely to die
due to any causes at any given point in time. Taking
estrogen or progesterone supplements for a longer
time and having more years of menstruation are
slightly protective factors against all-cause mortality.
There is no evidence that a nulliparous woman is
more likely to die due to any causes than a woman
with one or two live births; however, having more
than two live births decreases the probability of all-
cause mortality (HR 0.84 and 0.76 for three-four and
more than four live births, respectively). Breast self
examination (BSE) is another protective factor for all
Table 4 Characteristics of the study cohort: Lifestyle and health behaviours
Variable n= 89434(%)




Ever used oral contraceptives
Yes 53694 (60.04)
No 35740 (39.96)
Length of oral contraceptive used (months) (meanSD) 32.70(46.98)
Ever used estrogen, w/wo progesterone
Yes 24489 (27.38)
No 64945 (72.62)





0 per day 44343 (49.58)
Occasionally 1907 (2.13)
1-5 per day 6981 (7.81)
6-10 per day 9023 (10.09)
11-25 per day 21963 (24.56)
26-50 per day 4939 (5.52)
>50 per day 278 (0.31)
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though smoking less than 11 cigarettes per day does
not statistically significantly increase all-cause mor-
tality, smoking 11 or more cigarettes per day signifi-
cantly increases the probability of death due to any
causes. For example, a woman who smokes more
than 50 cigarettes per day is four times more at risk
of death than a non-smoker.
Women who have ever noted lumps in their breasts or
have had discharge from their breasts have respectively
1.3 and 1.5 times higher risk of death than those who
have not. Having the first child at age 14 to 19 is asso-
ciated with a 1.4-fold higher risk of death (HR 1.41, 95%
CI 1.14-1.74) than having the first child at age 20 to 25.Predictors of Cancer-specific Mortality
The predictors for mortality due to cancer (excluding
breast cancer) are presented in Table 7. “Age at entry”,
“length of estrogen/progesterone used”, “menstruation
length”, “breast self examination”, and “having the first
child birth at age 14-19” are factors having a similar or
the same effect on the risk of all-cause mortality and
mortality due to cancer. Women who have a bi-lateral
oophorectomy are 1.3 times more at risk of death due to
cancer than those who do not. As for all-cause mortality,
there is no evidence that a nulliparous woman is more
likely to die due to cancer than a woman with one or
two live births, but having more than two live births
decreases the probability of cancer death (HR 0.74 and
Table 5 Characteristics of the study cohort: history of
breast disease
Variable n= 89434(%)
Ever been told to have breast cancer
Yes 115 (0.13)
No 89319 (99.87)
Ever noted lumps in breasts
Yes 5139 (5.75)
No 84295 (94.25)
Ever noted pain in breasts
Yes 14951 (16.72)
No 74483 (83.28)
Ever noted discharge from breasts
Yes 1881 (2.10)
No 87553 (97.90)
Families with breast cancer score (meanSD) 14.77(21.22)
Ever have/had other types of breast disease
Yes 14363 (16.06)
No 75071 (83.94)
Abnormality in left breast found by nurse
Yes 14769 (16.51)
No 74665 (83.49)
Abnormality in right breast found by nurse
Yes 13748 (15.37)
No 75686 (84.63)
Female relatives with breast cancer
Yes 31574 (35.30)
No 57860 (64.70)
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evidence that a woman with more than 10 pregnancies
has a 3.3-fold greater risk of cancer death. Women who
smoke more than 10 cigarettes per day have a higher
risk of cancer mortality (HR 1.72, 2.90, and 2.78, respect-
ively, for smoking 11–25, 26–50, and > 50 cigarettes per
day).
Predictors of Non-cancer Mortality
Table 8 presents the factors found to be statistically sig-
nificant for non-cancer mortality. The table shows that
“age at entry” and “length of estrogen/progesterone
used” have similar effects on both non-cancer mortality
and all-cause mortality. In addition, women whose
ethnic origin was reported as not being Canadian have a
5-fold (HR 0.22, 95% CI 0.10-0.46) lower risk of non-
cancer mortality than women whose ethnic origin was
reported as Canadian. Women who have had a hysterec-
tomy are 1.3 times more likely to die from non-cancer
causes than those who have not. Women who reportedsmoking more than 10 cigarettes per day were found to
have a higher risk of non-cancer mortality (HR 1.82,
2.62, and 5.86, respectively, for smoking 11–25, 26–50,
and > 50 cigarettes per day). Finally, women who have
ever noted lumps in their breasts or have had discharge
from their breasts have respectively 1.6 and 2.0 times
more risk of non-cancer death than those who have not.
Table 9 compares the significant factors in all three
mortality models and the model for breast cancer inci-
dence [10] (factors for breast cancer incidence are
reported in detail in [10]). “Age at entry”, “length of es-
trogen/progesterone used (months)”, and “cigarettes
smoked per day” are common to the three morality
models. If we compare the significant risk factors for
mortality with those associated with breast cancer inci-
dence, we find “age at entry” appears in all four models.
“Menstruation length” and “number of live births” are
statistically significant risk factors for breast cancer inci-
dence, all-cause mortality, and cancer-specific mortality.
“Ever noted lumps in breasts” is associated with breast
cancer incidence, all-cause mortality, and non-cancer
mortality.
Discussion
In this study, we identify the predictors for all-cause
mortality, cancer-specific mortality (excluding mortality
from breast cancer), and non-cancer mortality. As previ-
ously reported, mortality due to causes other than breast
cancer is a competing risk for breast cancer incidence in
the data from the Canadian National Breast Screening
Study (CNBSS). It should be noted that we investigated
the associations for allocation group (no-mammography
vs. mammography) to both breast cancer incidence and
its competing mortality. We conducted univariate and
multivariate analyses, and in none of the models, did this
categorical variable reach statistical significance when
combined with other risk factors. This does not mean
there is no some real difference in breast cancer inci-
dence in these two groups, but the data do not show it
statistically. Otherwise, the analysis would have been
stratified by allocation group and separate results
obtained for each group. Therefore, to make use of a lar-
ger sample size for statistical analysis we combined all
the data without stratification by allocation group.
We found that using estrogen or progesterone supple-
ments for a longer time and longer menstruation are
both protective factors against all-cause mortality. These
results are consistent with other studies’ findings that
mortality among women who use hormones is lower
than among nonusers [17,18], and the later the onset of
menopause, the longer a woman is likely to live [19,20].
A negative association of these two factors with mortal-
ity could primarily be explained by reducing the occur-
rence of cardiovascular disease [18,19].
Figure 3 Ten-year cumulative risks by age groups. A, invasive breast cancer and the all-cause mortality. B, invasive breast cancer, the all-cause
mortality, cancer-specific and non-cancer mortalities.
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Table 6 Adjusted risk for all statistically significant factors for all-cause mortality excluding breast cancer death
Variable Parameter Estimate HR (95% CI) P-value
Age at entry 0.11115 1.12 (1.10-1.13) <.0001
Length of estrogen/progesterone used (months) −0.00285 0.997 (0.995-0.999) 0.0019
Menstruation length (years) −0.01088 0.989 (0.979-1.000) 0.0458
Had a hysterectomy (Ref*: No)
Yes 0.19090 1.21 (1.04-1.41) 0.0153
Number of live births (Ref: 1–2) 0.0282
Nulliparous −0.00203 0.998 (0.810-1.230) 0.9848
3-4 −0.17410 0.0300
>= 5 −0.27340 0.84 (0.72-0.98)0.76 (0.61-0.95) 0.0180
Breast self examination (BSE) practise (Ref: No)
Yes −0.18797 0.83 (0.73-0.94) 0.0048
Cigarettes smoked per day (Ref: 0 per day) <.0001
Occasionally 0.18753 1.21 (0.76-1.91)
1-5 per day 0.11747 1.13 (0.86-1.48) 0.4257
6-10 per day 0.04960 1.05(0.82-1.35) 0.3996
11-25 per day 0.55745 1.75 (1.50-2.04) 0.6960
26-50 per day 1.01296 2.75 (2.21-3.43) <.0001
>50 per day 1.39405 4.03 (2.08-7.82)
<.0001
<.0001
Ever noted lumps in breasts (Ref: No)
Yes 0.28345 1.33 (1.02-1.72) 0.0333
Ever noted discharge from breasts (Ref: No)
Yes 0.39762 1.49 (1.01-2.19) 0.0430
Age at first child birth (Ref: 20–25) 0.0053
14-19 0.34338 1.41 (1.14-1.74) 0.0016
26-30 −0.10960 0.90 (0.75-1.07) 0.2284
31-34 −0.08054 0.92 (0.68-1.25) 0.6017
35-39 −0.29037 0.75 (0.46-1.21) 0.2351
40-49 −1.16225 0.31 (0.04-2.23) 0.2463
Ref*: Reference level.
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mortality with number of live births. In the literature,
there is no consistent pattern of mortality with the num-
ber of births [21]. Some studies show a clear decrease in
mortality for women with 2–3 children compared to
nulliparous women, and a non-statistically significant in-
crease in the risk for women with more than three chil-
dren [22]. The result of some other studies is consistent
with our result and shows an overall negative association
between higher parity and mortality [23].
Similar to our result which shows an increase in the
risk of mortality when a woman has her first child at a
younger age (14–19), Grundy and Kravdal [23] also
found higher mortality for parents who had their firstchild at a younger age which tended to decrease with
older age at first birth.
Similar to the results from all-cause mortality, increase
in the number of live-births exhibits a decreasing trend
in the risk of cancer-specific mortality, although the nul-
liparous level does not reach statistical significance. As
the number of pregnancies increases the risk of cancer-
specific mortality increases as well, although only more
than ten times of pregnancy reaches statistical signifi-
cance. Moreover, increasing age at first child birth shows
a clear decreasing trend for risk of cancer-specific mor-
tality; however, only decrease in the risk of women who
had their first child-birth at age 20–25 compared to
those who had it at age 14–19 is statistically significant.
Table 7 Adjusted risk for all statistically significant factors for cancer-specific mortality
Variable Parameter Estimate HR (95% CI) P
Age at entry 0.10405 1.11 (1.09-1.13) <.0001
Length of estrogen/progesterone used (months) −0.00308 0.997 (0.995-0.999) 0.0132
Menstruation length (years) −0.01369 0.986 (0.974-0.999) 0.0406
Had a bi-lateral oophorectomy (Ref*: No)
Yes 0.29487 1.34 (1.05-1.72) 0.0206
Number of live births (Ref: 1–2) 0.0062
Nulliparous −0.08554 0.92 (0.69-1.22) 0.5574
3-4 −0.30281 0.74 (0.56-0.98) 0.0364
>= 5 −0.77717 0.46 (0.30-0.71) 0.0005
Breast self examination (BSE) practise (Ref: No)
Yes −0.17698 0.84 (0.71-0.94) 0.0424
Cigarettes smoked per day (Ref: 0 per day) <.0001
Occasionally 0.24987 1.28 (0.72-2.30) 0.3998
1-5 per day −0.01604 0.98 (0.68-1.44) 0.9335
6-10 per day −0.10999 0.90 (0.63-1.27) 0.5326
11-25 per day 0.54201 1.72 (1.41-2.10) <.0001
26-50 per day 1.06327 2.90 (2.19-3.83) <.0001
>50 per day 1.02201 2.78 (1.03-7.51) 0.0438
Number of pregnancies (Ref: 1–2) 0.0136
3-4 0.04212 1.04 (0.78-1.40) 0.7812
5-10 0.20064 1.22 (0.84-1.78) 0.2913
11-17 1.19964 3.32 (1.58-6.97) 0.0015
Age at first child birth (Ref: 20–25) 0.0185
14-19 0.33392 1.40 (1.06-1.84) 0.0185
26-30 −0.21654 0.81 (0.64-1.02) 0.0741
31-34 −0.28472 0.75 (0.50-1.14) 0.1824
35-39 −0.32799 0.72 (0.39-1.33) 0.2943
40-49 −0.68653 0.50 (0.07-3.60) 0.4942
Ref*: Reference level.
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http://www.biomedcentral.com/1471-2407/12/299We also found that women who were practicing BSE
on enrolment also had lower all-cause mortality. Argu-
ably, women who practice BSE are more likely to have
better personal health practices such as exercise, nutri-
tion, etc.
Event though we observe no trend in the first three
levels of the number of cigarettes smoked per day (i.e.
up to 11–25 cigarettes per day), the next three levels
clearly show an increasing trend in the risk in all three
mortality models.
Ever noting lumps in the breasts or having discharge
from the breasts are both associated with non-cancer
mortality. Although we do not have sufficient data to in-
vestigate biological association of these two factors with
each cause of mortality, one reason for increased risk of
non-cancer mortality could be anxiety caused by discov-
ery of a breast abnormality [24]. Women who experiencethe discovery will be coping with fears about the future
and dealing with emotional ups and downs [24].
By using the CNBSS, our study takes advantage of a
large cohort linked to the Canadian Cancer Registry and
the Mortality Database at Statistics Canada and relatively
complete data collected at the time of enrolment and
the initial physical examination of the breasts. This
makes our investigation of the association of 39 different
risk factors with breast cancer incidence [10] and its
competing mortality reliable.
Estimating the absolute risk of an event as accurately
as possible is fundamental in clinical decision-making
[25-28]. In the analysis of data in a competing risks set-
ting, both results for the event of interest and its com-
peting risks should be presented [29,30], and risk factors
for each competing risk identified [29]. The necessity for
analysis of both events of interest and their competing
Table 8 Adjusted risk for all statistically significant factors for non-cancer mortality
Variable Parameter Estimate HR (95% CI) P-value
Age at entry 0.11412 1.12 (1.10-1.14) <.0001
Length of estrogen/progesterone used (months) −0.00293 0.997 (0.994-1.000) 0.0398
Ethnic origin (Ref*: Canada)
Foreign −1.51760 0.22 (0.10-0.46) <.0001
Had a hysterectomy (Ref: No)
Yes 0.28427 1.33 (1.07-1.65) 0.0093
Cigarettes smoked per day (Ref: 0 per day) <.0001
Occasionally 0.08311 1.09 (0.51-2.32)
1-5 per day 0.27274 1.31 (0.88-1.96) 0.8298
6-10 per day 0.23232 1.26 (0.88-1.81) 0.1789
11-25 per day 0.59759 1.82 (1.43-2.31) 0.2057
26-50 per day 0.96370 2.62 (1.83-3.75) <.0001
>50 per day 1.76857 5.86 (2.40-14.30)
<.0001
0.0001
Ever noted lumps in breasts (Ref: No)
Yes 0.49413 1.64 (1.14-2.36) 0.0080
Ever noted discharge from breasts (Ref: No)
Yes 0.70502 2.02 (1.20-3.40) 0.0079
Ref*: Reference level.
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solute cause-specific risk (given in Appendix).
Moreover, describing the natural history of cancer and
possible pathways that an individual may go through is
an essential component of any simulation model which
is developed to assess the effectiveness of different inter-
vention policies. In a microsimulation model, the life
histories of many individuals are generated, and each
history substantially depends on the value of different
risk factors for a given individual. For example, a woman
who has a relative with breast cancer is at a higher risk
of being diagnosed with breast cancer at a younger age.
Other competing events, such as death due to different
causes can also be influenced by the risk factors. For ex-
ample, a woman aged 70 or above may die due to heart
attack before she is diagnosed with breast cancer. There-
fore, the effect of risk factors on all competing events
should be studied and described to model realistic life
paths of individuals. The simulation models could be ei-
ther developed for evaluating costs and benefits of can-
cer interventions at the population level, or for an
individual according to her risk factors, as the practice
of personalized medicine [31].
A cost-effective breast cancer screening policy relies
on knowing the absolute risk of breast cancer, and as
discussed, to obtain the absolute risk, competing risks
should also be studied and taken into account. Theabsolute risk can then be used to decide whether a
woman is categorized as high risk and whether a specific
intervention with higher frequency should be
recommended.
Gail et al. [32] developed an online risk assessment
tool to estimate a woman’s absolute risk of develop-
ing invasive breast cancer [33]. In this tool, the
absolute risk is estimated based on a woman’s risk
factors including age, family history of breast cancer,
number of biopsies, etc. A woman is identified at
high risk if her lifetime risk of invasive breast cancer
exceeds 20% [34]. Gail’s model [32] also investigates
competing risks, namely the age-specific risk of mor-
tality from causes other than breast cancer by using
national mortality rates.
Conclusions
In this study, we show that some risk factors are
statistically significant for both the main event of
interest (incidence of invasive breast cancer) and a
competing event (mortality due to non-breast cancer
causes). In addition, we identify other risk factors
associated with all-cause mortality and cause-specific
mortality. All these factors must be taken into ac-
count in estimating the probability of a competing
event. With more accurate estimation of the prob-
ability of a competing event, the estimations of
Table 9 Comparing the predictors of breast cancer incidence, all-cause mortality, cancer-specific mortality and non-
cancer mortality
Variable Breast cancer incidence All-cause mortality Cancer mortality Non-cancer mortality
Age at entry + + + +
Interaction of age at entry and time to event + - - -
Ethnic origin (Foreign) - - - +
Length of estrogen/progesterone used (months) - + + +
Menstruation length (years) + + + -
Had a hysterectomy - + - +
Had a bi-lateral oophorectomy - - + -
Number of live births + + + -
Interaction of nulliparous level and time to event + - - -
Breast Self examination (BSE) practise - + + -
Cigarettes smoked per day - + + +
Ever noted lumps in breasts + + - +
Interaction of lumps and time to event + - - -
Ever noted discharge from breasts - + - +
Ever have/had other types of breast disease + - - -
Abnormality in left breast found by nurse + - - -
Age at first child birth - + + -
Number of pregnancies - - + -
Families with breast cancer score + - - -
+ indicates the factor is significant
- indicates the factor is not significant
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estimated more precisely. This in turn leads to more
robust cost-effective analysis of preventive, diagnosis,
and treatment policies which are decided based on
the results of the absolute risk prediction model.
We used a cause-specific model to conduct regres-
sion analysis on our competing risks data. In
addition, we fitted the Fine-Gray model and the
results were very close to the results of the cause-
specific hazard model. The cause-specific model is
more clinically and biologically understandable since
it directly describes the effect of a covariate on a
specific cause and its hazard, regardless the effect of
other covariates [15,30]. In our data, the risk of both
breast cancer incidence [10] and its competing mor-
tality are minor, for which the Cox cause-specific
hazard is more reliable to be used [30]. Moreover,
the generality of hazard of subdistribution is
restricted to populations with similar characteristics
and competing risk rate [35], the latter being relaxed
in the cause-specific hazard model. On the other
hand, the subdistribution hazard can be used to cal-
culate the cumulative incidence function of the event
of interest and to directly interpret the effect of cov-
ariates on this function [36].Appendix-Calculating absolute cause-specific risk
When there are K competing causes, the cause-specific
hazard, which is defined as the instantaneous probability
of failing from cause k is
λk tð jZÞ ¼ limΔt!0 P t≤T≤t þ Δt;C ¼ kð jT≥t;ZÞ
Δt;
ð1Þ
where Z is a vector of covariates (risk factors), and the
overall hazard is λ tð jZÞ ¼PKk¼1λk tð jZÞ.
The absolute cause-specific risk or cumulative inci-
dence function (CIF) for cause k is defined as follows
[37]:
Ik tð jZÞ ¼ P T≤t;C ¼ kð Þ ¼
Z t
o
λk sð jZÞS sð jZÞds: ð2Þ
In equation (2), S tð jZÞ ¼ P T≥tð jZÞ ¼ eΛ tð jZÞ is the
overall survival function and Λ tð jZÞ ¼ Rt
0
λ sð jZÞds is the
cumulative hazard. Therefore, the cumulative hazard is a
function of all cause-specific hazards k ¼ 1; . . . ; K .
Equation (2) clearly shows that to obtain the cumulative
risk of an event of interest (in our case, breast cancer
Taghipour et al. BMC Cancer 2012, 12:299 Page 14 of 15
http://www.biomedcentral.com/1471-2407/12/299incidence), the cause-specific hazard for all competing
causes (competing mortality) should be also estimated.
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